Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Back on the scent: the olfactory system in CNS demyelinating diseases.
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
The nervous system's potential role in multiple sclerosis associated bone loss.
Vitamin B(12) Deficiency and Multiple Sclerosis; Is there Any Association?
FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model.
Preserved vascular integrity and enhanced survival following neuropilin-1 inhibition in a mouse model of CD8 T cell-initiated CNS vascular permeability.
Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis.
Multiple sclerosis and glutamate excitotoxicity.
Non-local robust detection of DTI white matter differences with small databases.
Can we safely target the WNT pathway?
Balance exercise program reduced falls in people with multiple sclerosis - a single group pretest posttest trial.
Increasing age at disability milestones among MS patients in the MSBase Registry.
NMO spectrum presenting as partial myelitis.
PLA2G6 mutations and other rare causes of Neurodegeneration with Brain Iron Accumulation.
Immune-related GTPase Irgm1 exacerbates experimental auto-immune encephalomyelitis by promoting the disruption of blood-brain barrier and blood-cerebrospinal fluid barrier.
Neuroaxonal regeneration is more pronounced in early multiple sclerosis than in traumatic brain injury lesions.
Th17 Cells: Biology, Pathogenesis of Autoimmune and Inflammatory Diseases, and Therapeutic Strategies.
Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders.
Inhibition of autoimmune encephalomyelitis by a tetracycline.
Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
Natalizumab discontinuation and disease restart in pregnancy: a case series.
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment.

Pages